Literature DB >> 10642871

Bovine respiratory disease: commercial vaccines currently available in Canada.

S L Bowland1, P E Shewen.   

Abstract

Bovine respiratory disease (BRD) remains a significant cost to both the beef and dairy industries. In the United States, an estimated 640 million dollars is lost annually due to BRD. Losses are largely a result of pneumonic pasteurellosis ("shipping fever"), enzootic pneumonia of calves, and atypical interstitial pneumonia. In Canada, over 80% of the biologics licensed for use in cattle are against agents associated with BRD. The objectives of this paper were (a) to summarize information available concerning commercial vaccines currently used in Canada for protection against BRD, and (b) to provide an easily accessible resource for veterinary practitioners and researchers. Information from the most recent Compendium of Veterinary Products has been tabulated for each vaccine by trade name, according to vaccine type, and the pathogens against which they are designed to protect. Additional information from published articles (peer-reviewed and other) has been provided and referenced.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10642871      PMCID: PMC1476343     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  44 in total

Review 1.  Rational basis for an immunization program against the common diseases of the bovine respiratory tract.

Authors:  R F Kahrs
Journal:  Can Vet J       Date:  1974-09       Impact factor: 1.008

2.  Statistical methods for analysis of in vitro antigen quantification data for veterinary biologic products.

Authors:  L A Wilbur
Journal:  Vet Microbiol       Date:  1993-11       Impact factor: 3.293

Review 3.  The pathogenesis of bovine virus diarrhoea virus infections.

Authors:  J Brownlie
Journal:  Rev Sci Tech       Date:  1990-03       Impact factor: 1.181

4.  The role of passive immunity in bovine respiratory syncytial virus-infected calves.

Authors:  E B Belknap; J C Baker; J S Patterson; R D Walker; D M Haines; E G Clark
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

Review 5.  Bovine respiratory tract disease caused by bovine viral diarrhea virus.

Authors:  L N Potgieter
Journal:  Vet Clin North Am Food Anim Pract       Date:  1997-11       Impact factor: 3.357

6.  Feedlot management practices and bovine respiratory disease.

Authors:  E G Johnson
Journal:  Vet Clin North Am Food Anim Pract       Date:  1985-07       Impact factor: 3.357

7.  Coronavirus isolation from nasal swab samples in cattle with signs of respiratory tract disease after shipping.

Authors:  J Storz; L Stine; A Liem; G A Anderson
Journal:  J Am Vet Med Assoc       Date:  1996-05-01       Impact factor: 1.936

8.  The effect of subunit or modified live bovine herpesvirus-1 vaccines on the efficacy of a recombinant Pasteurella haemolytica vaccine for the prevention of respiratory disease in feedlot calves.

Authors:  R J Harland; A A Potter; S van Drunen-Littel-van den Hurk; J Van Donkersgoed; M D Parker; T J Zamb; E D Janzen
Journal:  Can Vet J       Date:  1992-11       Impact factor: 1.008

9.  Passive immune status at postpartum hour 24 and long-term health and performance of calves.

Authors:  T E Wittum; L J Perino
Journal:  Am J Vet Res       Date:  1995-09       Impact factor: 1.156

Review 10.  Infectious bovine rhinotracheitis, parainfluenza-3, and respiratory coronavirus.

Authors:  S Kapil; R J Basaraba
Journal:  Vet Clin North Am Food Anim Pract       Date:  1997-11       Impact factor: 3.357

View more
  36 in total

1.  Another 2-way MLV vaccine against agents of bovine respiratory disease.

Authors:  B Vallée
Journal:  Can Vet J       Date:  2000-07       Impact factor: 1.008

2.  Mannheimia (Pasteurella) haemolytica leukotoxin binding domain lies within amino acids 1 to 291 of bovine CD18.

Authors:  R S Gopinath; T C Ambagala; M S Deshpande; R O Donis; S Srikumaran
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Inclusion of the bovine neutrophil beta-defensin 3 with glycoprotein D of bovine herpesvirus 1 in a DNA vaccine modulates immune responses of mice and cattle.

Authors:  Sarah Mackenzie-Dyck; Jennifer Kovacs-Nolan; Marlene Snider; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

Review 4.  Mammalian alphaherpesvirus miRNAs.

Authors:  Igor Jurak; Anthony Griffiths; Donald M Coen
Journal:  Biochim Biophys Acta       Date:  2011-06-28

5.  Localization of sequences within the latency-related gene of bovine herpesvirus 1 that inhibit mammalian cell growth.

Authors:  Vicki Geiser; Clinton Jones
Journal:  J Neurovirol       Date:  2005-12       Impact factor: 2.643

6.  Serum IgG response in calves to the putative pneumonic virulence factor Gs60 of Mannheimia haemolytica A1.

Authors:  Shahriar Orouji; Douglas C Hodgins; Reggie Y C Lo; Patricia E Shewen
Journal:  Can J Vet Res       Date:  2012-10       Impact factor: 1.310

7.  Genome sequences of Mannheimia haemolytica serotype A2: ovine and bovine isolates.

Authors:  Paulraj K Lawrence; Weerayuth Kittichotirat; Roger E Bumgarner; Jason E McDermott; David R Herndon; Donald P Knowles; Subramaniam Srikumaran
Journal:  J Bacteriol       Date:  2009-12-04       Impact factor: 3.490

8.  Sequence diversity and molecular evolution of the heat-modifiable outer membrane protein gene (ompA) of Mannheimia(Pasteurella) haemolytica, Mannheimia glucosida, and Pasteurella trehalosi.

Authors:  Robert L Davies; Inkyoung Lee
Journal:  J Bacteriol       Date:  2004-09       Impact factor: 3.490

9.  Identification of a novel bovine herpesvirus 1 transcript containing a small open reading frame that is expressed in trigeminal ganglia of latently infected cattle.

Authors:  Melissa Inman; Joe Zhou; Heather Webb; Clinton Jones
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Intact signal peptide of CD18, the beta-subunit of beta2-integrins, renders ruminants susceptible to Mannheimia haemolytica leukotoxin.

Authors:  Sudarvili Shanthalingam; Subramaniam Srikumaran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.